London-based Sava Technologies, a MedTech startup, recently closed a €16.6 million Series A funding round. Balderton Capital and Pentland Ventures led the investment. New participants included Norrsken VC and JamJar Investments. Other investors like True, Italian Founders Fund, Athletico Ventures, and Exceptional Ventures also joined. This brings Sava's total funding to €27.9 million.
Sava Technologies, founded in 2019 by Imperial College London bioengineers Renato Circi and Rafaël Michali, develops real-time molecular health monitoring. Their proprietary multi-molecule biosensor detects biomarkers just beneath the skin. The first product is a pain-free continuous glucose monitoring (CGM) device. This device streams molecular insights directly to a phone, offering a cost-effective alternative.
Advancing Real-Time Health Monitoring
The new capital will accelerate regulatory approval and commercialisation of Sava’s next-generation wearable technology. Funds will also expand the team and advance automated manufacturing capabilities. This investment further supports clinical validation of its microsensor technology.
An independent clinical trial, conducted in Oxford and Cambridge, involved 50 patients with Type 1 and insulin-dependent Type 2 diabetes. Early results from 25 patients demonstrated Sava’s technology delivered accurate glucose readings for up to 10 days. This duration surpasses many existing microsensor systems, which often fail within five days.
The global health wearables market exceeds $100 billion. Currently, only 1% of people with diabetes use CGMs, yet this segment generates over €9.6 billion in annual sales. Existing devices from companies like Abbott and Dexcom are often invasive or expensive. Sava aims to democratize access to glucose monitoring.
Beyond glucose, Sava’s modular platform can detect additional molecules. This multi-analyte sensing capability paves the way for a future of preventative and personalized healthcare. The company plans to introduce new molecules, creating new use cases for its biosensor technology.
